Therefore, a better understanding of the S1P/S1PR signaling pathway and developing specific inhibitors would provide the rationale and means to target the S1P/S1PR-signaling pathway for the benefit of patients with hematological malignancies upon allo-HCT. This evidence concerns the gene MBTPS1 and hematologic disorder.